Cyclerion Therapeutics Inc.
13F holders, Q3 2025 (September 30)17holders
3new positions
2sold out
$2.30avg. 13F price*
At the end of Q3 2025, 17 institutions reported holding Cyclerion Therapeutics Inc. in their 13F filings, unchanged from Q2 2025. 3 opened new positions and 2 sold out. The largest holders were Siren, L.L.C. ($267K), DRW Securities, LLC ($100K) and Geode Capital Management, LLC ($85K).
- Company
- Cyclerion Therapeutics Inc.
- CUSIP
- 23255M204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $131K |
| Exits | 2 | $64 |
All 13F filers, Q2 2025 → Q3 2025: 61,344 shares bought and 10,137 shares sold, net +51,207 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Siren, L.L.C. | 0.01% | No change | 116,155 | $267K |
| DRW Securities, LLC | 0.01% | New | 43,617 | $100K |
| Geode Capital Management, LLC | 0.00% | Add +13.5% | 37,158 | $85K |
| Vanguard Group Inc. | 0.00% | No change | 23,490 | $54K |
| BlackRock, Inc. | 0.00% | No change | 16,797 | $39K |
| Two Sigma Investments, LP | 0.00% | New | 13,293 | $31K |
| FMR LLC | 0.00% | Add +0.1% | 4,746 | $11K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -15.7% | 2,328 | $5K |
| Morgan Stanley | 0.00% | No change | 649 | $1K |
| Group One Trading LLC | 0.00% | No change | 192 | $442 |
| Osaic Holdings, Inc. | 0.00% | No change | 130 | $304 |
| MAI Capital Management | 0.00% | No change | 100 | $230 |
| Activest Wealth Management | 0.00% | No change | 100 | $230 |
| UBS Group AG | 0.00% | Reduce -99.5% | 49 | $113 |
| Bank of America Corp. | 0.00% | Reduce -8.3% | 22 | $50 |
| Barclays PLC | 0.00% | New | 5 | $12 |
| BNP Paribas Financial Markets | 0.00% | No change | 5 | $12 |
"% of holder's portfolio" is CYCLERION THERAPEUTICS INC's weight in each manager's 13F, not the share of Cyclerion Therapeutics Inc. the manager owns.